|
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
|
3 Months Ended | 9 Months Ended |
|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2012
Segment
|
|
| Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract] | ||
| Number of operating business segments | 1 | |
| Domestic revenue of sublingual buprenorphine formulations | $ 1,300,000,000 | |
| Non-cash loss on an increase in the fair value | $ 3,673,000 | |
| Iloperidone patent expiry year | 2016-10 | |
|
Minimum [Member]
|
||
| Organization and Summary of Significant Accounting Policies (Textual) [Abstract] | ||
| Royalty revenue percentage | 8.00% | |
|
Maximum [Member]
|
||
| Organization and Summary of Significant Accounting Policies (Textual) [Abstract] | ||
| Royalty revenue percentage | 10.00% |